Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome

European Heart Journal

Volumn 35, Issue 15, 2014, Pages 969-978

  Varenhorst, Christoph ^a   Jensevik, Karin ^a   Jernberg, Tomas ^b   Sundström, Anders ^c   Hasvold, Pål ^d,e   Held, Claes ^a   Lagerqvist, Bo ^a   James, Stefan ^a  

^a UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF OSLO   (Norway)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

Acute coronary syndrome; Antiplatelet treatment; Aspirin; Clopidogrel; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEATH; DUODENAL ULCER BLEEDING; FEMALE; HEART REINFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; STOMACH HEMORRHAGE; SUBARACHNOID HEMORRHAGE; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG ELUTING STENT; HOSPITALIZATION; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR; STENT; STROKE;

ACUTE CORONARY SYNDROME; AGED; ASPIRIN; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; STENTS; STROKE; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84898928011     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht438     Document Type: Article

References (23)

1. Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, Van't Hof A, Widimsky P, Zahger D, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569-2619
2. Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, WijnsW, Zahger D, Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevatio. Eur Heart J 2011;32:2999-3054
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
4. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015
5. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057
6. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fucà G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R. Shortversus long-Termduration of dual-Antiplatelet therapy after coronary stenting: A randomized multicenter trial. Circulation 2012;125:2015-2026
7. Park S-J, Park D-W, Kim Y-H, Kang S-J, Lee S-W, Lee CW, Han K-H, Park S-W, Yun S-C, Lee S-G, Rha S-W, Seong I-W, Jeong M-H, Hur S-H, Lee N-H, Yoon J, Yang J-Y, Lee B-K, Choi Y-J, Chung W-S, Lim D-S, Cheong S-S, Kim K-S, Chae JK, Nah D-Y, Jeon D-S, Seung KB, Jang J-S, Park HS, Lee K. Duration of dual antiplatelet therapy after implantation of drug-eluting stents.NEngl JMed 2010;362:1374-1382
8. Gwon H-C, Hahn J-Y, Park KW, Bin Song Y, Chae I-H, Lim D-S, Han K-R, Choi J-H, Choi S-H, Kang H-J, Koo B-K, Ahn T, Yoon J-H, Jeong M-H, Hong T-J, Chung W-Y, Choi Y-J, Hur S-H, Kwon H-M, Jeon D-W, Kim B-O, Park S-H, Lee N-H, Jeon H-K, Jang Y, Kim H-S. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505-513
9. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293: 2126-2130
10. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-Term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-168
11. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation 2006; 113:2803-2809
12. Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas JS, Ball MW, Caputo RP, Jain A, Tolleson TR, Reen BM, Kirtane AJ, Fitzgerald PJ, Thompson K, Kandzari DE. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010;55:543-554
13. KimuraT, MorimotoT, NakagawaY, TamuraT, Kadota K, Yasumoto H, NishikawaH, HiasaY, MuramatsuT, MeguroT, Inoue N, Honda H, HayashiY, Miyazaki S, Oshima S, HondaT, Shiode N, Namura M, SoneT, Nobuyoshi M, KitaT, Mitsudo K. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009;119:987-995
14. Sarno G, Lagerqvist B, Fröbert O, Nilsson J, Olivecrona G, Omerovic E, Saleh N, Venetzanos D, James S. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: A report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012;33:606-613
15. Jernberg T, Attebring MF, Hambraeus K, Ivert T, James S, Jeppsson A, Lagerqvist B, Lindahl B, Stenestrand U, Wallentin L. The SwedishWeb-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart (British Cardiac Society) 2010;96: 1617-1621
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Disease 1987;40:373-383
17. Ducrocq G, Wallace JS, Baron G, Ravaud P, Alberts MJ, Wilson PWF, Ohman EM, Brennan DM, D'Agostino RB, Bhatt DL, Steg PG. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J 2010;31: 1257-1265.
18. Tada T, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Byrne RA, Kastrati A, Kadota K, Iwabuchi M, Shizuta S, Tazaki J, Shiomi H, Abe M, Ehara N, Mizoguchi T, Mitsuoka H, Inada T, Araki M, Kaburagi S, Taniguchi R, Eizawa H, Nakano A, Suwa S, Takizawa A, Nohara R, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T. Duration of dual antiplatelet therapy and long-Term clinical outcome after coronary drug-eluting stent implantation: Landmark analyses from theCREDOKyoto PCI/CABG Registry Cohort-2. Circ Cardiovasc Intervent 2012;5:381-391
19. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann F-J, Schömig A, Kastrati A. Periprocedural bleeding and 1-yearoutcome after percutaneous coronary interventions: Appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008;51:690-697
20. Kim B-K, Hong M-K, Shin D-H, Nam C-M, Kim J-S, Ko Y-G, Choi D, Kang T-S, Park B-E, Kang W-C, Lee S-H, Yoon J-H, Hong B-K, Kwon H-M, Jang Y. A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimuseluting stent implantation). J Am Coll Cardiol 2012;60:1340-1348
21. Byrne RA, Schulz S, Mehilli J, Iijima R, Massberg S, Neumann F-J, ten Berg JM, Schömig A, Kastrati A. Rationale and design of a randomized, double-blind, placebocontrolled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual. Am Heart J 2009;157:620-624.e2
22. Feres F, Costa RA, Bhatt DL, Leon MB, Botelho RV, King SB, de Paula JET, Mangione JA, Salvadori D, Gusmão MO, Castello H, Nicolela E, Perin MA, Devito FS, Marin-Neto JA, AbizaidA. Optimized Duration of clopidogrel therapy following treatment with the endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: Rationale and design of a large-scale, randomized, multicenter study. Am Heart J 2012;164:810-816.e3
23. Mauri L, Kereiakes DJ, Normand S-LT, Wiviott SD, Cohen DJ, Holmes DR, Bangalore S, Cutlip DE, Pencina M, Massaro JM. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary. Am Heart J 2010;160:1035-1041, 1041.e1